Lakewood-Amedex Biotherapeutics, Inc.
NASDAQLakewood-Amedex Biotherapeutics has become one of the most expensive stocks to short on the Nasdaq this week, with its borrow market tightening at a pace that is almost without precedent for a name this small. The cost-to-borrow story is the standout. At 423% annualised as of April 30 — nearly tripling from 161% just three sessions earlier on April 27 — borrowing LABT…
LABT short borrow utilization hits 100%, up from 27.4% yesterday. Cost to borrow surges to 423% as stock drops 26%.
Snapshot as of 19 Oct 2026
Lakewood-Amedex Biotherapeutics has become one of the most expensive stocks to short on the Nasdaq this week, with its borrow market tightening at a pace that is almost without precedent for a name this small. The…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for LABT — free to start on ORTEX.
Sign up for free →Open LABT on ORTEX